An Australian stem cell and regenerative medicine company
About Us
About Us
What We Do
Board Of Directors
Management
Scientific Advisors
Corporate Governance
Company History
Clinical Development
Graft-versus-host-disease
Osteoarthritis
Acute respiratory distress syndrome
Diabetic Wounds
Renal transplantation
Pre-clinical Development
Asthma
Heart Attack
Coronary Artery Disease
Brain Cancer
Sepsis
Critical Limb Ischemia
Idiopathic pulmonary fibrosis
Science & Technology
Cymerus Technology
About MSCs
About iPSCs
Science Publications
Investors
Stock Information
ASX Announcements
Financial Results
Presentations
Corporate Governance
Analyst Research
Investor FAQs
Right to Receive Documents
Newsroom
FAQ
Company FAQs
Investor FAQs
Contact Us
Science Publications
Vodyanik MA, Yu J, Zhang X, et al. A Mesoderm-Derived Precursor for Mesenchymal Stem and Endothelial Cells. Cell Stem Cell 2010;7(6):718-29.
Kelly K. Limitless starting materials for large-scale manufacture of MSCs – what does the future hold? Pharm Bioprocess. 2015;3:281-283.
Koch JM, D’Souza SS, Schwahn DJ, et al. Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice. Cytotherapy 2016;18:219–228.
Royce SG, Rele S, Broughton BRS, et al. Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease. FASEB J. 2017;31(9):4168-4178.
Kelly K. Next-generation cell-based therapies: the potential of IPSCs. Australasian Biotechnology. 2017;27(3):14-16.
Royce SG, Mao WY, Lim R, et al. iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid. FASEB J. 2019;15:fj201802307R.
Ozay EI, Vijayaraghavan J, Gonzalez-Perez G, et al. Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease. Stem Cell Res. 2019;35:101401.
Kelly K. Can iPSCs Address the Challenge of Maintaining Consistent Quality in Starting Materials Used in the Manufacture of Cell-Based Therapies? Cell & Gene Therapy Insights. 2019; 5(2), 227-232.
Khan MA, Alanazi F, Ahmed HA, et al. iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in mouse orthotopic tracheal transplants. Stem Cell Res Ther. 2019;23;10(1):290.
Millar JE, Bartnikowski N, Passmore MR. Combined Mesenchymal Stromal Cell Therapy and Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep. Am J Respir Crit Care Med. 2020 Aug 1;202(3):383-392.
Bloor AC, Patel A, Griffin JE, et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med. 2020;26(11):1720-1725.
Kelly K, Rasko JEJ. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. Front Immunol. 2021;12:761616.
Liu X, Robbins S, Wag X, et al. Efficacy and cost-effectiveness of Stem Cell injections for symptomatic relief and strUctural improvement in people with Tibiofemoral knee OsteoaRthritis: protocol for a randomised placebo-controlled trial (the SCUlpTOR trial). BMJ Open. 2021;11(11):e056382.
Thavapalachandran S, Le TYL, Romanazzo S. Pluripotent stem cell-derived mesenchymal stromal cells improve cardiac function and vascularity after myocardial infarction. Cytotherapy. 2021;23(12):1074-1084.
Romanazzo S, Kopecky C, Jiang S, et al. Biomaterials directed activation of a cryostable therapeutic secretome in induced pluripotent stem cell derived mesenchymal stromal cells. Tissue Eng Regen Med. 2022;16(11):1008-1018.
Results of the First Completed Clinical Trial of an iPSC-Derived Product: CYP-001 in Steroid-Resistant Acute GvHD
A comparative analysis of the MSC transcriptome: Human iPSC-derived MSCs and their tissue-derived counterparts